ATE537150T1 - Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate - Google Patents

Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate

Info

Publication number
ATE537150T1
ATE537150T1 AT06809167T AT06809167T ATE537150T1 AT E537150 T1 ATE537150 T1 AT E537150T1 AT 06809167 T AT06809167 T AT 06809167T AT 06809167 T AT06809167 T AT 06809167T AT E537150 T1 ATE537150 T1 AT E537150T1
Authority
AT
Austria
Prior art keywords
treatment
pyrazole derivatives
gynecological diseases
derivatives suitable
gynecological
Prior art date
Application number
AT06809167T
Other languages
English (en)
Inventor
Paul Bradley
Kevin DACK
Patrick Johnson
Sarah Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE537150T1 publication Critical patent/ATE537150T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06809167T 2005-11-08 2006-10-26 Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate ATE537150T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73509105P 2005-11-08 2005-11-08
PCT/IB2006/003080 WO2007054770A2 (en) 2005-11-08 2006-10-26 Pyrazole derivatives and their medical use

Publications (1)

Publication Number Publication Date
ATE537150T1 true ATE537150T1 (de) 2011-12-15

Family

ID=37909834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809167T ATE537150T1 (de) 2005-11-08 2006-10-26 Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate

Country Status (35)

Country Link
US (2) US7309712B2 (de)
EP (1) EP1948615B1 (de)
JP (1) JP4234786B1 (de)
KR (1) KR100997595B1 (de)
CN (1) CN101304974A (de)
AP (1) AP2008004463A0 (de)
AR (1) AR056780A1 (de)
AT (1) ATE537150T1 (de)
AU (1) AU2006313478A1 (de)
BR (1) BRPI0618630A2 (de)
CA (1) CA2628844C (de)
CR (1) CR9959A (de)
CY (1) CY1112286T1 (de)
DK (1) DK1948615T3 (de)
DO (1) DOP2006000245A (de)
EA (1) EA014693B1 (de)
EC (1) ECSP088431A (de)
ES (1) ES2376252T3 (de)
GT (1) GT200600478A (de)
HN (1) HN2006037713A (de)
IL (1) IL190806A0 (de)
MA (1) MA29940B1 (de)
NL (1) NL2000299C2 (de)
NO (1) NO20082504L (de)
PE (1) PE20070642A1 (de)
PL (1) PL1948615T3 (de)
PT (1) PT1948615E (de)
RS (1) RS20080191A (de)
SI (1) SI1948615T1 (de)
TN (1) TNSN08202A1 (de)
TW (1) TWI321563B (de)
UA (1) UA90763C2 (de)
UY (1) UY29904A1 (de)
WO (1) WO2007054770A2 (de)
ZA (1) ZA200803670B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
KR100997595B1 (ko) * 2005-11-08 2010-11-30 화이자 리미티드 피라졸 유도체 및 이의 의약 용도
EP2081905B1 (de) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl verbindungen als cb2 rezeptor modulatoren
CN101516839A (zh) 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
JP5492092B2 (ja) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
EP2418207A1 (de) * 2008-05-13 2012-02-15 Boehringer Ingelheim International GmbH CB2-Rezeptor modulierende Sulfonverbindungen
JP5749162B2 (ja) 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するスルホン化合物
BRPI0919172A2 (pt) 2008-09-25 2015-12-15 Boehringer Ingelheim Int compostos os quais modulam seletivamente o receptor de cb2
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (de) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidin 2 -carboxamidderivate als cb2-rezeptormodulatoren
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
EP2595959B1 (de) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonylverbindungen zur modulierung des cb2-rezeptors
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
AU2019362242A1 (en) * 2018-10-18 2021-05-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as TGF-β R1 inhibitor and application thereof
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
CN111269097B (zh) * 2020-04-02 2023-02-17 苏州爱玛特生物科技有限公司 一种多元环双取代的1,3-丙二酮类化合物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281638A (ja) * 1985-10-07 1987-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS63313784A (ja) * 1987-03-12 1988-12-21 Zeria Shinyaku Kogyo Kk 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤
DE4414792A1 (de) * 1993-08-11 1995-02-16 Bayer Ag Arzneimittel enthaltend 1-Thiocarbamoyl-5-hydroxypyrazolen und deren Verwendung als Mittel zur Bekämpfung des septischen Schocks
DE60219292T2 (de) 2001-04-10 2008-04-10 Pfizer Inc. Pyrazolderivate zur behandlung von hiv
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
KR100997595B1 (ko) * 2005-11-08 2010-11-30 화이자 리미티드 피라졸 유도체 및 이의 의약 용도

Also Published As

Publication number Publication date
TNSN08202A1 (fr) 2009-10-30
IL190806A0 (en) 2008-11-03
HN2006037713A (es) 2010-06-09
AR056780A1 (es) 2007-10-24
KR100997595B1 (ko) 2010-11-30
EA014693B1 (ru) 2010-12-30
GT200600478A (es) 2007-06-08
UY29904A1 (es) 2007-06-29
NL2000299C2 (nl) 2007-11-20
UA90763C2 (ru) 2010-05-25
SI1948615T1 (sl) 2012-02-29
DOP2006000245A (es) 2007-06-30
DK1948615T3 (da) 2012-02-06
CY1112286T1 (el) 2015-12-09
US20080085919A1 (en) 2008-04-10
AP2008004463A0 (en) 2008-06-30
TW200804295A (en) 2008-01-16
EA200801053A1 (ru) 2008-10-30
KR20080056761A (ko) 2008-06-23
MA29940B1 (fr) 2008-11-03
TWI321563B (en) 2010-03-11
PT1948615E (pt) 2012-02-03
PE20070642A1 (es) 2007-08-24
WO2007054770A3 (en) 2007-10-04
AU2006313478A1 (en) 2007-05-18
WO2007054770A2 (en) 2007-05-18
PL1948615T3 (pl) 2012-04-30
RS20080191A (en) 2009-07-15
EP1948615A2 (de) 2008-07-30
ES2376252T3 (es) 2012-03-12
EP1948615B1 (de) 2011-12-14
NO20082504L (no) 2008-06-05
CA2628844A1 (en) 2007-05-18
US7309712B2 (en) 2007-12-18
JP4234786B1 (ja) 2009-03-04
US20070105909A1 (en) 2007-05-10
NL2000299A1 (nl) 2007-05-09
US7425569B2 (en) 2008-09-16
ECSP088431A (es) 2008-06-30
ZA200803670B (en) 2009-03-25
CA2628844C (en) 2011-12-06
CN101304974A (zh) 2008-11-12
CR9959A (es) 2008-08-01
JP2009514938A (ja) 2009-04-09
BRPI0618630A2 (pt) 2011-09-06

Similar Documents

Publication Publication Date Title
ATE537150T1 (de) Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
DE602007011906D1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
ATE484279T1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE439843T1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
PL1890705T3 (pl) Zastosowanie 24-nor-UDCA do leczenia cholestatycznych chorób wątroby
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen